Ask Onix
Financial sacrifices pay off for self-funded patient
Ruth Gonzalez, 56, began taking Eli Lilly's Zepbound last year after her blood pressure spiked, but the $350 monthly cost forced her to cut back on groceries, streaming services, and her mobile plan. The investment paid off: her blood pressure normalized within six weeks, and she has since lost over 40 pounds, improving conditions like sleep apnea and early-stage fatty liver disease.
Gonzalez, who is self-employed and lacks insurance coverage for weight-loss medications, says recent price cuts by Eli Lilly-reducing vial costs by $50 to $100-have eased her financial strain. She now takes a higher dose and is eyeing an upcoming lower-cost pill from the company.
"For someone on a fixed budget, it is absolutely helpful," she says.
Pharmaceutical firms slash prices amid fierce competition
Gonzalez's experience reflects a broader trend in the U.S., where drugmakers are aggressively competing for a share of the weight-loss market. With nearly 40% of American adults classified as obese, the potential for sales is massive-but insurers have largely refused to cover GLP-1 medications like Zepbound and Novo Nordisk's Wegovy solely for weight loss.
This resistance has pushed pharmaceutical companies to adopt retail-like strategies, including direct-to-consumer sales, partnerships with retailers like Walmart and Costco, and legal battles against off-label competitors. The most significant shift has been price cuts: Wegovy's starting dose now costs $149 per month for self-pay patients, down from over $1,600 at its 2021 launch. Zepbound's vials start at $299, a steep drop from its 2023 debut price of over $1,000.
Direct-to-consumer model sparks debate on drug pricing
The price reductions have sparked discussions about whether the direct-to-consumer approach could help lower U.S. drug costs by increasing transparency and sidelining pharmacy benefit managers (PBMs), who negotiate prices between manufacturers and insurers.
"What it does is highlight some of the lack of transparency," says Alison Sexton Ward, a senior scholar at USC. "So... it is pushing this idea of direct-to-consumer."
Former President Donald Trump has championed the model, with the White House launching TrumpRx in February-a website directing customers to manufacturers for select medications. Drugmakers, who have long blamed PBMs for inflating costs, are now exploring direct sales for other drugs.
However, experts caution that the competitive dynamics driving GLP-1 price cuts may not apply to other medications, where demand is narrower and fewer competitors exist. Off-label alternatives, which emerged legally during shortages, have also complicated the market.
Insurance gaps leave many without access
Despite the price cuts, weight-loss drugs remain unaffordable for many. Shekinah Samayah-Thomas, 62, has been rationing her remaining Wegovy supply since January, when California's Medicaid program stopped covering it for weight loss. The medication helped her maintain weight loss after bariatric surgery in 2017, but without coverage, even a $25 monthly copay-once manageable with her husband's insurance and a manufacturer coupon-is now out of reach.
"I don't have it," she says.
Health advocates argue that market competition is an imperfect solution. Tracy Zvenyach, vice president for advocacy and research at the Obesity Action Coalition, notes that the Trump administration's decision to allow Medicare to cover the drugs on a trial basis starting in July could have a broader impact if private insurers follow suit.
"Direct-to-consumer options today are serving as a short-term solution. But I do not want them to deter from the overall goals of general, standard coverage of treatments for obesity," Zvenyach says.
Systemic challenges persist
While the price war has provided relief for some, experts emphasize the need for systemic reforms. Michael Murphy, a professor of clinical pharmacy at Ohio State University, acknowledges the role of consumer awareness but stresses the need for broader solutions to reduce overall healthcare costs.
"Hopefully this will drive additional consumer awareness of the drivers of the high costs of medication. But we need to see further, more fundamental solutions be employed to actually bring down costs overall to the system," Murphy says.
For now, the U.S. remains a global outlier in drug pricing, with weight-loss medications still priced higher than in many other countries. Analysts expect further declines as patents expire and new, lower-cost alternatives enter the market.
